TG Therapeutics Inc vs TJX Companies Inc — how do they compare? TG Therapeutics Inc trades at $54.77 (market cap $8.53B), while TJX Companies Inc trades at $126.69 (market cap $141.81B). The key difference: TJX Companies Inc is far larger — about 16.6× TG Therapeutics Inc's market cap, and TJX Companies Inc pays a 1.49% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | TJX | |
|---|---|---|
Market Cap | $8.53B | $141.81B |
Sector | Health | Consumer Cyclical |
52-Week High | $59.06 | $168.41 |
52-Week Low | $26.94 | $126.10 |
Enterprise Value | $8.74B | $150.12B |
Dividend Yield | — | 1.49% |
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
TJX Companies (TJX) trades at $128.91, down 2.4% over 24 hours, with technical indicators showing bearish momentum but oversold RSI signals. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.22 exceeding expectations. Revenue grew to $56.36 billion in 2025, and net income margin improved to 9.73%. Analysts maintain a bullish consensus with 84.6% buy ratings and a $169 price target, citing expansion plans to 7,500 stores.
The outlook for TJX is positive due to consistent earnings outperformance and robust store growth strategy, though near-term stock pressure reflects valuation concerns and competitive comparisons. Key risks include market volatility and execution challenges in scaling operations. Investors may find opportunity in the current dip given strong fundamentals and analyst support.
Trailing returns across standard periods
Latest headlines on both assets
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →